Osteoporosis

Latest

Bone Density Linked to Vascular Calcification in ESRD

Bone Density Linked to Vascular Calcification in ESRD

A prospective cohort study in 66 patients with end-stage renal disease was conducted to determine the link between renal and coronary heart diseases.

Long-Term DPP-4 Inhibitor Use Not Associated With Fracture Risk in Type 2 Diabetes

Long-Term DPP-4 Inhibitor Use Not Associated With Fracture Risk in Type 2 Diabetes

For patients with type 2 diabetes, long-term use of dipeptidyl peptidase-4 (DPP-4) inhibitors is not associated with fracture risk.

VIDEO: Clinical Trial Results for Abaloparatide

Lorraine Fitzpatrick, MD, discusses updated results from the ACTIVE phase 3 clinical trial.

Does Antihypertensive Medication Class Affect Fracture Risk?

Does Antihypertensive Medication Class Affect Fracture Risk?

Researchers compared 3 classes of antihypertensive medication to determine hip and pelvic fracture risk in users vs nonusers.

New Osteoporosis Treatment Options on the Horizon

Nancy E. Lane, MD, professor of medicine, at the University of California at Davis School of Medicine, discusses results from the phase 3 ACTIVE trial.

Bone Density Lower Among Heavy Cannabis Users

Bone Density Lower Among Heavy Cannabis Users

Heavy cannabis users have lower bone density compared to cigarette smokers.

Bone Mineral Density Linked to Concentrations of 25(OH)D in Summer

Bone Mineral Density Linked to Concentrations of 25(OH)D in Summer

Summer levels of serum 25-hydroxyvitamin D are associated with bone mineral density of the total hip.

AACE/ACE Updates Postmenopausal Osteoporosis Management Guidelines

AACE/ACE Updates Postmenopausal Osteoporosis Management Guidelines

The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) announced the publication of new clinical guidelines and an accompanying algorithm to help physicians and other health care professionals with the diagnosis, fracture risk assessment, and treatment of postmenopausal osteoporosis.

Fracture Risk in Diabetes No Higher With Sitagliptin

Fracture Risk in Diabetes No Higher With Sitagliptin

According to results from the TECOS trial, sitagliptin is not linked to an increased risk for fractures in patients with diabetes.

Fracture Risk Lower With Abaloparatide in Osteoporosis

Fracture Risk Lower With Abaloparatide in Osteoporosis

In postmenopausal women with osteoporosis, an experimental drug appears to reduce the risk of bone fractures better than teriparatide or a placebo.

Sign Up for Free e-Newsletters